In a report published in Hepatology, scientists from the FDA’s Division of Antiviral Products in the Center for Drug Evaluation and Research (CDER) have provided a brief overview of the FDA’s...
WASHINGTON – A simple dietary challenge may help identify nonceliac gluten sensitivity in patients with gastrointestinal functional disorders, resul... More »
Achieving a cure in hepatitis C infection could result in significant economic gains, with a study estimating that the beneficial effects in terms of ... More »
WASHINGTON – The course of Crohn’s disease has changed for the better since the introduction of biological therapies and other treatments in the l... More »
VIENNA – All-oral HCV therapy with grazoprevir and elbasvir plus sofosbuvir achieved high, sustained virologic response (SVR) rates at 12 weeks afte... More »
VIENNA – Delaying hepatitis C virus (HVC) treatment can have a detrimental effect on the outcomes of some patients, according to the results of a la... More »
VIENNA – More than 75% of patients with decompensated cirrhosis due to chronic hepatitis C virus (HCV) infection achieved a sustained virologic resp... More »
A 12-week course of oral daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin, achieved a sustained virologic response (SVR) in patient... More »
VIENNA – Patients infected with hepatitis C virus who developed cirrhosis and received statin treatment had significantly lower rates of both death ... More »
VIENNA– In addition to dramatically increasing the risk of liver cancer more than 68-fold, chronic hepatitis C virus (HCV) infection more than doubl... More »